European experience of steroid therapy in children with developmental and epileptic encephalopathy with spike wave activation in sleep ((D)EE-SWAS)
Steroids are part of the first line therapy of (D)EE-SWAS across Europe, but heterogeneity in formulations, dosages, and regimens persists due to limited guideline availability. The absence of comparative studies and the discordant definitions of (D)EE-SWAS further hinder comparisons of treatment efficacy. We recommend that harmonizing steroid treatment strategies is imperative for optimizing (D)EE-SWAS management.
Authors
- Kerstin Alexandra Klotz (ORCID: https://orcid.org/0000-0002-1601-5384)
- Floor E. Jansen (ORCID: https://orcid.org/0000-0003-0745-5668)
- Victoria San Antonio‐Arce (ORCID: https://orcid.org/0000-0002-2780-6560)
- Jan Schönberger (ORCID: https://orcid.org/0000-0002-5448-7825)
- Julia Jacobs (ORCID: https://orcid.org/0000-0003-1164-4699)
- Dilan Canbay
Institutions
- University of Freiburg (DE)
- Heidelberg University (DE)
- Center of Advanced European Studies and Research (DE)
- University Medical Center Freiburg (DE)
- Alberta Children's Hospital (CA)
- University Hospital Heidelberg (DE)
- University Medical Center Utrecht (NL)
Publication Details
- Journal
- Orphanet Journal of Rare Diseases
- Published
- 2025-04-29
- DOI
- https://doi.org/10.1186/s13023-025-03725-0
- Citations
- 4
- Primary Topic
- Epilepsy research and treatment
- Type
- article
- Field-Weighted Citation Impact
- 5.88